Alembic Pharmaceuticals Ltd is benefiting from the boost pharma firms have been getting during the covid-19 lockdown. On a year-on-year basis, its revenue and profitability have been running slightly ahead of expectations.
The company has been a beneficiary of covid-19 pre-stocking due to the six-week lockdown in the domestic market. Revenue from acute therapy drugs grew 24% year-on-year which benefited from the extended flu season, while revenue from its specialty products was up 10%.
This has shored up its Q4 FY20 domestic formulations business about 13.2% year-on-year, higher than its past growth figures. Click here to enlarge graphic Alembic’s shares have risen 67% from their lows in March and are now close to all-time highs.